<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "http://jats.nlm.nih.gov/publishing/1.0/JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.0" specific-use="sps-1.8" xml:lang="es" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
	<front>
		<journal-meta>
			<journal-id journal-id-type="publisher-id">ode</journal-id>
			<journal-title-group>
				<journal-title>Odontoestomatología</journal-title>
				<abbrev-journal-title abbrev-type="publisher">Odontoestomatología</abbrev-journal-title>
			</journal-title-group>
			<issn pub-type="ppub">0797-0374</issn>
			<issn pub-type="epub">1688-9339</issn>
			<publisher>
				<publisher-name>Facultad de Odontología - Universidad de la República</publisher-name>
			</publisher>
		</journal-meta>
		<article-meta>
			<article-id pub-id-type="doi">10.22592/ode2020n35a7</article-id>
			<article-id pub-id-type="publisher-id">00007</article-id>
			<article-categories>
				<subj-group subj-group-type="heading">
					<subject>Investigación</subject>
				</subj-group>
			</article-categories>
			<title-group>
				<article-title>Perfil inmunohistoquímico del mixoma odontogénico, con énfasis en marcadores de agresividad tumoral y microdensidad vascular</article-title>
				<trans-title-group xml:lang="en">
					<trans-title>Immunohistochemical profile of odontogenic myxoma, with emphasis on microvascular density and tumor aggressiveness markers</trans-title>
				</trans-title-group>
				<trans-title-group xml:lang="pt">
					<trans-title>Perfil imuno-histoquímico do mixoma odontogênico, com ênfase em marcadores de agressividade tumoral e microdensidade vascular</trans-title>
				</trans-title-group>
			</title-group>
			<contrib-group>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0002-1925-0291</contrib-id>
					<name>
						<surname>Gómez-Herrera</surname>
						<given-names>Zaira</given-names>
					</name>
					<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0001-5365-2692</contrib-id>
					<name>
						<surname>Sánchez-Romero</surname>
						<given-names>Celeste</given-names>
					</name>
					<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0002-0617-1279</contrib-id>
					<name>
						<surname>Vigil-Bastitta</surname>
						<given-names>Gabriela</given-names>
					</name>
					<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0001-7747-6718</contrib-id>
					<name>
						<surname>Pereira-Prado</surname>
						<given-names>Vanesa</given-names>
					</name>
					<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0003-1137-6866</contrib-id>
					<name>
						<surname>Sicco</surname>
						<given-names>Estefania</given-names>
					</name>
					<xref ref-type="aff" rid="aff5"><sup>5</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0002-2798-1596</contrib-id>
					<name>
						<surname>Tremillo-Maldonado</surname>
						<given-names>Omar</given-names>
					</name>
					<xref ref-type="aff" rid="aff6"><sup>6</sup></xref>
				</contrib>
				<contrib contrib-type="author">
					<contrib-id contrib-id-type="orcid">0000-0001-9755-4779</contrib-id>
					<name>
						<surname>Bologna-Molina</surname>
						<given-names>Ronell</given-names>
					</name>
					<xref ref-type="aff" rid="aff7"><sup>7</sup></xref>
				</contrib>
			</contrib-group>
			<aff id="aff1">
				<label>1</label>
				<institution content-type="original"> Departamento de Atención a la Salud, Universidad Autónoma Metropolitana (UAM), México</institution>
				<institution content-type="normalized">Universidad Autónoma Metropolitana</institution>
				<institution content-type="orgdiv1">Departamento de Atención a la Salud</institution>
				<institution content-type="orgname">Universidad Autónoma Metropolitana</institution>
				<country country="MX">Mexico</country>
			</aff>
			<aff id="aff2">
				<label>2 </label>
				<institution content-type="original">Área de Patología Molecular Estomatológica, Facultad de Odontología, Universidad de la República, Uruguay, csr_90@hotmail.com</institution>
				<institution content-type="normalized">Universidad de la República</institution>
				<institution content-type="orgdiv2">Área de Patología Molecular Estomatológica</institution>
				<institution content-type="orgdiv1">Facultad de Odontología</institution>
				<institution content-type="orgname">Universidad de la República</institution>
				<country country="UY">Uruguay</country>
				<email>csr_90@hotmail.com</email>
			</aff>
			<aff id="aff3">
				<label>3</label>
				<institution content-type="original"> Área de Patología Molecular Estomatológica, Facultad de Odontología, Universidad de la República, Uruguay</institution>
				<institution content-type="normalized">Universidad de la República</institution>
				<institution content-type="orgdiv2">Área de Patología Molecular Estomatológica</institution>
				<institution content-type="orgdiv1">Facultad de Odontología</institution>
				<institution content-type="orgname">Universidad de la República</institution>
				<country country="UY">Uruguay</country>
			</aff>
			<aff id="aff4">
				<label>4</label>
				<institution content-type="original"> Área de Patología Molecular Estomatológica, Facultad de Odontología, Universidad de la República, Uruguay</institution>
				<institution content-type="normalized">Universidad de la República</institution>
				<institution content-type="orgdiv2">Área de Patología Molecular Estomatológica</institution>
				<institution content-type="orgdiv1">Facultad de Odontología</institution>
				<institution content-type="orgname">Universidad de la República</institution>
				<country country="UY">Uruguay</country>
			</aff>
			<aff id="aff5">
				<label>5</label>
				<institution content-type="original"> Área de Patología Molecular Estomatológica, Facultad de Odontología, Universidad de la República, Uruguay</institution>
				<institution content-type="normalized">Universidad de la República</institution>
				<institution content-type="orgdiv2">Área de Patología Molecular Estomatológica</institution>
				<institution content-type="orgdiv1">Facultad de Odontología</institution>
				<institution content-type="orgname">Universidad de la República</institution>
				<country country="UY">Uruguay</country>
			</aff>
			<aff id="aff6">
				<label>6</label>
				<institution content-type="original"> Universidad Autónoma Metropolitana de México, unidad Xochimilco, México</institution>
				<institution content-type="orgname">Universidad Autónoma Metropolitana de México</institution>
				<institution content-type="normalized">Universidad Autónoma Metropolitana de México</institution>
				<institution content-type="orgdiv1">unidad Xochimilco</institution>
				<country country="MX">México</country>
			</aff>
			<aff id="aff7">
				<label>7</label>
				<institution content-type="original"> Patología Molecular Estomatológica, Facultad de Odontología, Universidad de la República, Uruguay</institution>
				<institution content-type="normalized">Universidad de la República</institution>
				<institution content-type="orgdiv2">Patología Molecular Estomatológica</institution>
				<institution content-type="orgdiv1">Facultad de Odontología</institution>
				<institution content-type="orgname">Universidad de la República</institution>
				<country country="UY">Uruguay</country>
			</aff>
			<!--pub-date date-type="pub" publication-format="electronic">
				<day>01</day>
				<month>06</month>
				<year>2020</year>
			</pub-date>
			<pub-date date-type="collection" publication-format="electronic"-->
			<pub-date pub-type="epub-ppub">
				<month>06</month>
				<year>2020</year>
			</pub-date>
			<volume>XXII</volume>
			<issue>35</issue>
			<fpage>52</fpage>
			<lpage>61</lpage>
			<history>
				<date date-type="received">
					<day>25</day>
					<month>07</month>
					<year>2019</year>
				</date>
				<date date-type="accepted">
					<day>09</day>
					<month>12</month>
					<year>2019</year>
				</date>
			</history>
			<permissions>
				<license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/" xml:lang="es">
					<license-p>Este es un artículo publicado en acceso abierto bajo una licencia Creative Commons</license-p>
				</license>
			</permissions>
			<abstract>
				<title>Resumen:</title>
				<p>Con el fin de tener una mayor comprensión sobre el comportamiento biológico del mixoma odontogénico (MO), se realizó inmunohistoquímica en 31 muestras, utilizando marcadores relacionados con mecanismos de progresión tumoral (adhesión, angiogénesis, apoptosis, inflamación y proliferación celular). Epitelio odontogénico fue detectado en cuatro muestras mediante CK19 y CD138, este último, mostró expresión baja en matriz extracelular (MEC) y alta en las células tumorales. La microdensidad vascular (MDV) media fue de 7.51 y 5.35 vasos marcados con CD34 y VEGF-A respectivamente. Una alta expresión de Orosomucoide-1 y Mast Cell Tryptase se observó células tumorales y en MEC. El MO mostró negatividad para Calretinina. Este perfil inmunohistoquímico, la baja expresión para Ki-67, Bcl-2 y p53, y la relativamente baja MDV, sugieren que la actividad proliferativa, anti-apoptótica o angiogénica no representan los principales mecanismos de crecimiento del MO, los cuales podrían estar asociados a eventos como inmunomodulación y degradación de la MEC.</p>
			</abstract>
			<trans-abstract xml:lang="en">
				<title>Abstract:</title>
				<p>In order to elucidate better the biological behavior of the odontogenic myxoma (OM), immunohistochemistry was performed in 31 samples, using markers related to mechanisms of tumor progression (adhesion, angiogenesis, apoptosis, inflammation and cell proliferation). Odontogenic epithelium was detected in four samples with CK19 and CD138, the latter had a low-expression in extracellular matrix (ECM) and a high-expression in tumor cells. The mean microvascular density (MVD) assessed with CD34 and VEGF-A, was 7.51 and 5.35 blood vessels respectively. A high-expression of Orosomucoid-1 and Mast Cell Tryptase was observed in tumor cells and ECM, while Calretinin was completely negative. The previously mentioned immunohistochemical profile, as well as the low expression of Ki-67, Bcl-2 and p53 and the relatively low MVD, suggests that the proliferative, anti-apoptotic and angiogenic activities do not represent the main growing mechanisms of OM, which could be associated to other events, such as immunomodulation and ECM degradation.</p>
			</trans-abstract>
			<trans-abstract xml:lang="pt">
				<title>Resumo:</title>
				<p>Para melhor compreensão do comportamento biológico do mixoma odontogênico (MO), imuno-histoquímica foi realizada em 31 amostras, utilizando marcadores relacionados aos mecanismos de progressão tumoral (adesão, angiogênese, apoptose, inflamação e proliferação celular). Epitélio odontogênico foi detectado em quatro amostras por CK19 e CD138, o último mostrou baixa expressão na matriz extracelular (MEC) e alta em células tumorais. A microdensidade vascular (MDV) média foi de 7.51 e 5.35 vasos marcados com CD34 e VEGF-A, respectivamente. Uma alta expressão de Orosomucoide-1 e Mast Cell Tryptase foi observada nas células tumorais e na MEC. O MO mostrou negatividade para Calretinina. O perfil imuno-histoquímico mencionado acima, a baixa expressão de Ki-67, Bcl-2 e p53 e a relativamente baixa MDV, sugerem que a atividade proliferativa, anti-apoptótica ou angiogênica não representam os principais mecanismos de crescimento do MO, os quais poderiam estar associados com eventos como imunomodulação e degradação da MEC.</p>
			</trans-abstract>
			<kwd-group xml:lang="es">
				<title>Palabras clave:</title>
				<kwd>mixoma odontogénico</kwd>
				<kwd>inmunohistoquímica</kwd>
				<kwd>marcadores tumorales</kwd>
				<kwd>angiogénesis</kwd>
			</kwd-group>
			<kwd-group xml:lang="en">
				<title>Keywords:</title>
				<kwd>odontogenic myxoma</kwd>
				<kwd>immunohistochemistry</kwd>
				<kwd>tumoral markers</kwd>
				<kwd>angiogenesis.</kwd>
			</kwd-group>
			<kwd-group xml:lang="pt">
				<title>Palavras-chave:</title>
				<kwd>mixoma odontogênico</kwd>
				<kwd>imuno-histoquímica</kwd>
				<kwd>marcadores tumorais</kwd>
				<kwd>angiogênese</kwd>
			</kwd-group>
			<counts>
				<fig-count count="2"/>
				<table-count count="3"/>
				<equation-count count="0"/>
				<ref-count count="30"/>
				<page-count count="10"/>
			</counts>
		</article-meta>
	</front>
	<body>
		<sec sec-type="intro">
			<title>Introducción</title>
			<p>Los tumores odontogénicos (TO) constituyen un espectro de lesiones que afecta principalmente a los huesos gnáticos, e incluye desde proliferaciones hamartomatosas hasta neoplasias benignas y tumores malignos <xref ref-type="bibr" rid="B1"><sup>1</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B2"><sup>2</sup></xref>. El mixoma odontogénico (MO) es un TO mesenquimal benigno (con o sin epitelio odontogénico), sin embargo, presenta un comportamiento agresivo: un importante potencial de crecimiento, así como un alto índice de recurrencia (25%) <xref ref-type="bibr" rid="B3"><sup>3</sup></xref>.</p>
			<p>Mundialmente, los MO representan entre el 2.2 y el 17% de los TO y afectan principalmente la zona posterior de mandíbula, y ocasionalmente el maxilar <xref ref-type="bibr" rid="B4"><sup>4</sup></xref>. Raros casos de MO periférico han sido reportados, siendo menos agresivos que el MO central <xref ref-type="bibr" rid="B5"><sup>5</sup></xref>. El MO ocurre con mayor frecuencia entre la segunda y cuarta décadas de vida (media 28.6 años), y clínicamente se presenta como un aumento de volumen de crecimiento lento, generalmente asintomático <xref ref-type="bibr" rid="B6"><sup>6</sup></xref>, por lo que puede alcanzar grandes dimensiones al momento del diagnóstico. Radiográficamente el aspecto puede ser unilocular (lesiones pequeñas), o más comúnmente multilocular (clásicamente descrito como “raqueta de tenis”) <xref ref-type="bibr" rid="B3"><sup>3</sup></xref>.</p>
			<p>Microscópicamente, el MO se caracteriza por la presencia de células fusiformes a estrelladas dispersas en una abundante matriz mixoide compuesta principalmente por glicosaminoglicanos, pudiendo presentar o no islas de epitelio odontogénico, la presencia de fibras de colágeno es variable <sup>(3,4 6,)</sup>.</p>
			<p>A la fecha existen pocos trabajos que describan los componentes moleculares del MO, por lo cual, el objetivo de este trabajo es establecer un perfil inmunohistoquímico de diversos marcadores tumorales y analizar la microdensidad vascular (MDV) con el fin de discutir sus posibles implicaciones en el comportamiento biológico del MO.</p>
		</sec>
		<sec sec-type="methods">
			<title>Metodología</title>
			<sec>
				<title>Selección de la muestra</title>
				<p>Se incluyeron 31 casos de MO mandibulares obtenidos del Área de Patología Molecular de la Facultad de Odontología de la Universidad de la República (Uruguay). Dichas muestras se obtuvieron mediante biopsia incisional, fueron fijadas en formaldehido al 10% y posteriormente se incluyeron en bloques de parafina. Este trabajo fue aprobado por el Comité de Ética de la Facultad de Odontología de la Universidad de la República, número de protocolo: 091900-000113-14. Se obtuvo el consentimiento informado de todos los participantes incluidos en el estudio, al momento de la toma de biopsia.</p>
			</sec>
			<sec>
				<title>Inmunohistoquímica</title>
				<p>Se realizaron cortes de 3µm y se colocaron sobre laminillas, los cortes se desparafinaron en xilol y posteriormente se hidrataron mediante baños en concentraciones decrecientes de alcohol. Para la recuperación antigénica se utilizó una solución de citrato de (pH 6.2) en olla de presión-horno de microondas a máxima potencia por un minuto. Para el bloqueo de la peroxidasa endógena, se utilizó peróxido de hidrógeno al 0,9%, durante 5 minutos. Los anticuerpos primarios para fueron incubados durante una hora (<xref ref-type="table" rid="t1">Tabla 1</xref>).</p>
				<p>
					<table-wrap id="t1">
						<label>Tabla 1:</label>
						<caption>
							<title>Datos de los anticuerpos utilizados en este estudio</title>
						</caption>
						<graphic xlink:href="1688-9339-ode-22-35-52-gt1.jpg"/>
					</table-wrap>
				</p>
				<p>Posteriormente, los cortes se incubaron con el anticuerpo secundario biotinilado anti-ratón/anti conejo y con el complejo streptavidina/peroxidasa (LSA-B+Dako Corporation, Carpintería CA, USA) por 30 minutos cada uno. La reacción se visualizó con sustrato de 3,3’-diaminobenzidinaH2O2 (Dako Corporation, Carpintería, CA, USA). Por último, los cortes fueron contrastados con hematoxilina de Mayer.</p>
				<p>Como controles positivos se utilizaron: mucosa oral para CK19 y CD138; cáncer de mama para Calretinina; carcinoma oral para Orosomucoide-1 y p53; intestino para Mast Cell Tryptase, CD34 y VEGF-A; y amígdala Bcl-2 y Ki-67.</p>
			</sec>
			<sec>
				<title>Análisis microscópico</title>
				<p>Las reacciones fueron consideradas positivas al observar marcación marrón celular (células tumorales, endoteliales o de islas de epitelio odontogénico), o en la matriz extracelular (MEC). Los patrones de marcación (nuclear, citoplasmática, membranosa o de MEC) varían con cada tipo de anticuerpo.</p>
				<p><italic>Proteínas evaluadas en islas de epitelio odontogénico: CK19 y CD138</italic></p>
				<p>Cada corte fue visualizado por completo bajo un objetivo de 10x para identificar las áreas de positividad y, posteriormente, a 40x para confirmar que se tratara de epitelio odontogénico. El resultado se expresó como positivo o negativo. </p>
				<p><italic>Proteínas evaluadas en células tumorales y matriz extracelular: CD138, Calretinina, Orosomucoide-1, Mast Cell Tryptase, Bcl-2, Ki-67, p53 y VEGF-A.</italic></p>
				<p>En un microscopio óptico, se visualizaron los cortes completos bajo el objetivo de 40x para determinar un porcentaje de inmunoexpresión en la totalidad del tejido tumoral presente en la laminilla. Los porcentajes se clasificaron en 4 grupos: 0%, expresión negativa; de 1% a 10%, expresión baja; 11% a 50%, expresión moderada y mayor de 50% expresión alta <xref ref-type="bibr" rid="B7"><sup>7</sup></xref>.</p>
				<p><italic>Proteínas evaluadas en vasos sanguíneos: VEGF-A y CD34.</italic></p>
				<p>Para determinar la MDV, se empleó el método descrito por Weidner et al. Los tejidos fueron visualizados inicialmente bajo un objetivo de 10x, para identificar 3 zonas con la mayor concentración de vasos positivos (<italic>hot spots</italic>), en las cuales, bajo el objetivo de 40x se realizó el contaje de vasos manualmente. Finalmente se calculó la media del número de vasos en los cinco campos de cada muestra <xref ref-type="bibr" rid="B8"><sup>8</sup></xref>.</p>
			</sec>
		</sec>
		<sec sec-type="results">
			<title>Resultados</title>
			<p>Epitelio odontogénico positivo para CK19 y CD138 fue detectado en cuatro casos. Adicionalmente CD138 mostró una inmunoexpresión alta en las células tumorales de la mayoría de las muestras (74.2%) y una expresión baja en la MEC en el 38.7% de los casos (<xref ref-type="fig" rid="f1">Figura 1</xref> A, B). </p>
			<p>Calretinina fue negativa en todas las muestras de MO. Por el contrario, fue observada alta inmunopositividad de Orosomucoide-1 en células tumorales y MEC en el 100% de los casos, mientras que Mast Cell Tryptase pudo observarse en forma de gránulos mastocitos, focalmente en la MEC y con una alta expresión en las células tumorales 96.7% de los casos (n=30) (<xref ref-type="fig" rid="f2">Figura 2</xref> A, D) (<xref ref-type="fig" rid="f2">Figura 2</xref> C, E, F). </p>
			<p>Una baja marcación de Bcl-2 (citoplasmática), Ki-67 (nuclear) y p53 (nuclear) fue observada en las células tumorales (n=18, 58.1%; n=28, 90.3% y n=12, 38.7% respectivamente).</p>
			<p>CD34 y VEGF-A fueron positivas en las células endoteliales (vasos sanguíneos). Adicionalmente, VEGF-A mostró una expresión predominantemente alta en las células tumorales del MO (n=24, 77.5%) (<xref ref-type="table" rid="t2">Tabla 2</xref>). La MDV fue de 7.51 vasos con CD34 y 5.35 vasos con VEGF-A (<xref ref-type="fig" rid="f1">Figuras 1</xref>C y <xref ref-type="fig" rid="f2">2D</xref>).</p>
			<p>La mayoría de las proteínas que fueron detectadas en células tumorales y en MEC tuvieron una inmunoexpresión alta, a excepción de Bcl-2. La <xref ref-type="table" rid="t3">tabla 3</xref> muestra el patrón, nivel y distribución de inmunoexpresión de cada proteína en los casos de MO.</p>
			<p>
				<fig id="f1">
					<label>Fig. 1:</label>
					<caption>
						<title>Marcadores inmunohistoquímicos en mixoma odontogénico. Pequeñas islas de epitelio odontogénico mostraron positividad para CK19 (A), y CD138 (B), la cual también se expresó en células tumorales y MEC. Únicamente las células endoteliales de los vasos sanguíneos mostraron positividad para CD34 (C). (Magnificación original, A-C: 400x).</title>
					</caption>
					<graphic xlink:href="1688-9339-ode-22-35-52-gf1.jpg"/>
				</fig>
			</p>
			<p>
				<fig id="f2">
					<label>Fig. 2:</label>
					<caption>
						<title>Perfil inmunohistoquímico del mixoma odontogénico</title>
					</caption>
					<alt-text>Alta inmunopositividad de Orosomucoide-1 en células tumorales, células endoteliales y MEC (A). Expresión de VEGF-A en células tumorales y células endoteliales (B). Baja marcación de Bcl-2 en algunas células tumorales (C). Mast Cell Tryptase intensamente positiva con aspecto granular en las células tumorales, mastocitos y MEC (D). Escasos núcleos positivos para Ki-67 (E) y p53 (F). (Magnificación original, A, B, C, E, F: 400x; D: 600x)</alt-text>
					<graphic xlink:href="1688-9339-ode-22-35-52-gf2.jpg"/>
				</fig>
			</p>
			<p>
				<table-wrap id="t2">
					<label>Tabla 2:</label>
					<caption>
						<title>Distribución de la expresión de los marcadores dentro de los componentes del mixoma odontogénico</title>
					</caption>
					<graphic xlink:href="1688-9339-ode-22-35-52-gt2.jpg"/>
					<table-wrap-foot>
						<fn id="TFN1">
							<p>Abreviaciones. CT: células tumorales, MEC: matriz extracelular, EO: epitelio odontogénico, VS: vasos sanguíneos</p>
						</fn>
					</table-wrap-foot>
				</table-wrap>
			</p>
			<p>
				<table-wrap id="t3">
					<label>Tabla 3:</label>
					<caption>
						<title>Número y porcentaje de casos de acuerdo al nivel de inmunoexpresión que presentaron</title>
					</caption>
					<graphic xlink:href="1688-9339-ode-22-35-52-gt3.jpg"/>
					<table-wrap-foot>
						<fn id="TFN2">
							<p>Abreviaciones CT: células tumorales, M:mastocitos. MEC: matriz extracelular *La expresión de VEGF-A en células endoteliales fue cuantificada como microdensidad vascular (ver en sección de resultados) </p>
						</fn>
					</table-wrap-foot>
				</table-wrap>
			</p>
		</sec>
		<sec sec-type="discussion">
			<title>Discusión</title>
			<p>Se ha propuesto un origen odontogénico del MO con base en la presencia ocasional de pequeñas islas de epitelio odontogénico, su localización en mandíbula y maxilares, y su similitud histomorfológica con la porción mesenquimal del germen dentario <xref ref-type="bibr" rid="B9"><sup>9</sup></xref>.</p>
			<p>En el presente estudio, en el 13.3% de la muestra se encontraron islas de epitelio odontogénico positivas para CD138 y CK19, coincidiendo con estudios anteriores en los que usando CK19, se detectaron islas epiteliales en el 4.8% y 14% de los casos <xref ref-type="bibr" rid="B9"><sup>9</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B10"><sup>10</sup></xref><sup>).</sup> Adicionalmente, nuestros resultados corroboran la utilidad de CD138 como un marcador alternativo de epitelio odontogénico en el MO.</p>
			<p>Una alta expresión de CD138 fue observada en células tumorales en la mayoría de los casos (73.30%), mientras que, en la MEC, la inmunoexpresión fue principalmente baja (46.70% de los casos). Contrario a nuestros resultados, en el estudio de Etemad-Moghadam et al. (2017) CD138 fue negativo en todas sus muestras <xref ref-type="bibr" rid="B11"><sup>11</sup></xref>. El papel fisiológico de CD138, en conjunto con la MEC es la participación en la inducción y regulación de la proliferación mediante la interacción con familias de factores de crecimiento ligados a la heparina <xref ref-type="bibr" rid="B12"><sup>12</sup></xref>; además, interactúa con otros componentes de la MEC <xref ref-type="bibr" rid="B13"><sup>13</sup></xref>, algunos de los cuales (colágeno tipo I, fibronectina y tenascina) forman parte de la MEC del MO <xref ref-type="bibr" rid="B14"><sup>14</sup></xref>, sugiriendo así que CD138, además de la función de mantenimiento estructural propia de una proteína de adhesión epitelial, al ser liberada en la MEC, podría estar involucrada en diversas vías de señalización al interactuar con factores de crecimiento y otras moléculas presentes en la MEC. </p>
			<p>A pesar de que la expresión de calretinina ha sido descrita en ameloblastomas, y ha sido asociada a la producción de esmalte en germen dentario, en nuestro estudio resultó negativa en MO, al igual que en trabajos previos <xref ref-type="bibr" rid="B15"><sup>15</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B16"><sup>16</sup></xref>. Esta ausencia de calretinina puede ser explicada por el origen mesenquimal del MO, a diferencia del ameloblastoma y el órgano del esmalte <xref ref-type="bibr" rid="B17"><sup>17</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B18"><sup>18</sup></xref>.</p>
			<p>Un estudio previo determinó la MDV en el MO mediante CD34, mostrando resultados similares a los nuestros <xref ref-type="bibr" rid="B7"><sup>7</sup></xref>. El ameloblastoma presenta una mayor MDV comparado con otros tumores y quistes odontogénicos, lo que sugiere una asociación con un comportamiento más agresivo <xref ref-type="bibr" rid="B19"><sup>19</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B20"><sup>20</sup></xref>. En nuestro estudio, el MO mostró una MDV aproximadamente 5 veces menor que los ameloblastomas del estudio de Seifi et al. (2001), sugiriendo que, en el MO, la angiogénesis podría contribuir limitadamente al potencial de crecimiento tumoral <xref ref-type="bibr" rid="B19"><sup>19</sup></xref>.</p>
			<p>En MO, VEGF-A (una de las principales proteínas señalizadoras para la angiogénesis), se expresó en células endoteliales y en las células tumorales. Investigaciones recientes sugieren que la inmunoexpresión de VEGF-A en el epitelio de quistes odontogénicos y TO epiteliales como el ameloblastoma, influye en la proliferación epitelial mediante un mecanismo autócrino; mientras que la actividad anigiogénica mediada por un mecanismo parácrino <xref ref-type="bibr" rid="B7"><sup>7</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B21"><sup>21</sup></xref>. Sin embargo, en el único estudio describiendo la expresión de VEGF-A en MO, se ha asociado principalmente a mecanismos angiogénicos de este tumor <xref ref-type="bibr" rid="B7"><sup>7</sup></xref>. </p>
			<p>En las muestras de MO analizadas, se observó una inmunoexpresión alta de Orosomucoide-1 en células tumorales y MEC. Confirmando los hallazgos de los dos estudios que reportaron la sobreexpresión de Orosomucoide-1 en MO mediante inmunohistoquímica y preoteómica <xref ref-type="bibr" rid="B7"><sup>7</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B22"><sup>22</sup></xref>.</p>
			<p>Macroscópicamente, el MO tiene la apariencia de una masa mucoide altamente viscosa, la cual, de acuerdo a nuestros resultados, podría deberse en parte a la presencia de Orosomucoide-1 (que es una mucoproteína) en la MEC. Es ampliamente aceptado que la viscosidad estructural del MO, le confiere la habilidad de infiltrar e invadir <xref ref-type="bibr" rid="B7"><sup>7</sup></xref>. Por otra parte, García Muñoz et al. (2012), propusieron que la sobreexpresión de Orosomucoide-1 en el MO podría jugar un papel importante en el crecimiento y potencial de invasión de las células tumorales, al inhibir respuesta inmune antitumoral <xref ref-type="bibr" rid="B22"><sup>22</sup></xref>.</p>
			<p>Se ha demostrado que Orosomucoide-1 participa en la regulación e inducción de VEGF-A.<xref ref-type="bibr" rid="B23"><sup>23</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B24"><sup>24</sup></xref><sup>)</sup> De esta manera, la sobreexpresión de ambas proteínas en las células tumorales y endoteliales del MO podría indicar una interacción entre Orosomucoide-1 y VEGF-A en este tumor, indicando con un rol colaborativo pro-angiogénico <xref ref-type="bibr" rid="B7"><sup>7</sup></xref>.</p>
			<p>En el presente estudio, la mayoría de los casos expresaron inmunopositividad alta para Mast Cell Tryptase (96,70%) en células tumorales, mastocitos y MEC. Un estudio previo en siete casos de MO, reportó la ausencia de expresión de Mast Cell Tryptase; sin embargo, el tamaño de la muestra podría no ser representativa <xref ref-type="bibr" rid="B25"><sup>25</sup></xref>. Otra pesquisa en una muestra mayor (62 casos), encontró la presencia de Mast Cell Tryptase en el 72.6% de los MO localizándose principalmente en los mastocitos, los cuales contienen grandes cantidades de triptasa activa almacenada que al ser liberada es capaz de degradar fibronectina (uno de los componentes de la MEC del MO), lo que sugiere que, en parte, la degradación de la MEC podría estar mediada por la liberación de Mast Cell Tryptase.<xref ref-type="bibr" rid="B9"><sup>9</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B26"><sup>26</sup></xref><sup>)</sup> Adicionalmente, existe una asociación relación entre la presencia de mastocitos y Mast Cell Tryptase con la reabsorción ósea en quistes odontogénicos <xref ref-type="bibr" rid="B27"><sup>27</sup></xref>, y a pesar de que la incidencia de mastocitos en el MO es variable entre algunos estudios, se ha descrito que estas células frecuentemente se distribuyen adyacente a trabéculas óseas residuales <xref ref-type="bibr" rid="B28"><sup>28</sup></xref>. Dichos hallazgos sugieren que la degradación de la MEC y procesos de remodelación ósea mediante la triptasa, contribuye de manera importante en el potencial de invasión del MO <xref ref-type="bibr" rid="B27"><sup>27</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B28"><sup>28</sup></xref>.</p>
			<p>El desbalance entre los mecanismos de apoptosis y proliferación celular representan importantes alteraciones moleculares tumorigénicas en diversas neoplasias. </p>
			<p>En el presente estudio fueron evaluadas p53, Bcl-2 y Ki-67, proteínas relacionadas con procesos apoptóticos, anti apoptóticos y de proliferación celular respectivamente. Se ha demostrado que la apoptosis inducida por p53 puede ser bloqueada por Bcl-2 <xref ref-type="bibr" rid="B29"><sup>29</sup></xref>. Al igual que p53, Bcl-2 mostró una baja inmunoexpresión en la mayoría de los MO, lo que coincide con reportes previos <xref ref-type="bibr" rid="B9"><sup>9</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B30"><sup>30</sup></xref>. De igual manera, Ki-67 mostró un bajo índice proliferativo en nuestros casos coincidiendo con diversos autores <xref ref-type="bibr" rid="B9"><sup>9</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B30"><sup>30</sup></xref>, Estos resultados podrían indicar que, debido al bajo nivel de actividad anti-apoptótica y proliferativa en este tumor, estos no serían los principales mecanismos asociados a el potencial de crecimiento y agresividad del MO.</p>
		</sec>
		<sec sec-type="conclusions">
			<title>Conclusiones</title>
			<p>La marcación CK19 y CD138 es útil para detectar epitelio odontogénico en el MO. La alta expresión de Orosomucoide-1 en la MEC lo indica como un componente estructural que contribuye a su viscosidad y, por ende, facilitando la invasión. Orosomucoide-1 también mostró un patrón semejante a VEGF-A en las células tumorales y endoteliales, sugiriendo una actividad colaborativa pro-angiogénica, posiblemente implicada en el desarrollo tumoral. La actividad anti-apoptótica y proliferativa no se perfilan como mecanismos cruciales en el comportamiento agresivo del MO. Sin embargo, la degradación de la MEC y la reabsorción ósea mediada por Mast Cell Tryptase, podrían ser importantes para el alto potencial invasivo del MO.</p>
		</sec>
	</body>
	<back>
		<ref-list>
			<title>Referencias</title>
			<ref id="B1">
				<label>1</label>
				<mixed-citation>1. El-Naggar Chan JKC, Grandis JR, Takata T, Slootweg P, editors. WHO classification of Head and Neck Tumours. Chapter 8: Odontogenic and maxilofacial bone tumours. 4th edition, IARC: Lyon 2017, p.205-260.</mixed-citation>
				<element-citation publication-type="book">
					<person-group person-group-type="author">
						<name>
							<surname>El-Naggar Chan</surname>
							<given-names>JKC</given-names>
						</name>
						<name>
							<surname>Grandis</surname>
							<given-names>JR</given-names>
						</name>
						<name>
							<surname>Takata</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Slootweg</surname>
							<given-names>P</given-names>
						</name>
					</person-group>
					<source>WHO classification of Head and Neck Tumours</source>
					<chapter-title>Chapter 8: Odontogenic and maxilofacial bone tumours</chapter-title>
					<edition>4th edition</edition>
					<publisher-name>IARC</publisher-name>
					<publisher-loc>Lyon</publisher-loc>
					<year>2017</year>
					<fpage>205</fpage>
					<lpage>260</lpage>
				</element-citation>
			</ref>
			<ref id="B2">
				<label>2</label>
				<mixed-citation>2. Mosqueda-Taylor A, Ledesma-Montes C, Caballero-Sandoval S, Portilla-Robertson J, Ruíz-Godoy RLM, Meneses-García A. Odontogenic tumors in México. A collaborative retrospective study of 349 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997; 84 (6): 672-5.</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Mosqueda-Taylor</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Ledesma-Montes</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Caballero-Sandoval</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Portilla-Robertson</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Ruíz-Godoy</surname>
							<given-names>RLM</given-names>
						</name>
						<name>
							<surname>Meneses-García</surname>
							<given-names>A</given-names>
						</name>
					</person-group>
					<article-title>Odontogenic tumors in México A collaborative retrospective study of 349 cases</article-title>
					<source>Oral Surg Oral Med Oral Pathol Oral Radiol Endod</source>
					<year>1997</year>
					<volume>84</volume>
					<issue>6</issue>
					<fpage>672</fpage>
					<lpage>675</lpage>
				</element-citation>
			</ref>
			<ref id="B3">
				<label>3</label>
				<mixed-citation>3. Wright JM, Soluk-Tekkesin M. Odontogenic tumors: where are we in 2017? J Istanb Univ Fac Dent. 2017; 51 (3 Suppl 1): s10-30.</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Wright</surname>
							<given-names>JM</given-names>
						</name>
						<name>
							<surname>Soluk-Tekkesin</surname>
							<given-names>M</given-names>
						</name>
					</person-group>
					<article-title>Odontogenic tumors where are we in 2017?</article-title>
					<source>J Istanb Univ Fac Dent</source>
					<year>2017</year>
					<volume>51</volume>
					<issue>3 Suppl 1</issue>
					<fpage>s10</fpage>
					<lpage>s30</lpage>
				</element-citation>
			</ref>
			<ref id="B4">
				<label>4</label>
				<mixed-citation>4. Gonzalez-Galvan MC, Mosqueda-Taylor A, Bologna-Molina R, Setien-Olarra A, Marichalar-Mendia X, Aguirre-Urizar JM. Evaluation of the osteoclastogenic process associated with RANK / RANK-L / OPG in odontogenic myxomas. Med Oral Patol Oral Cir Bucal. 2018; 23 (3): e315-9.</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Gonzalez-Galvan</surname>
							<given-names>MC</given-names>
						</name>
						<name>
							<surname>Mosqueda-Taylor</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Bologna-Molina</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Setien-Olarra</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Marichalar-Mendia</surname>
							<given-names>X</given-names>
						</name>
						<name>
							<surname>Aguirre-Urizar</surname>
							<given-names>JM</given-names>
						</name>
					</person-group>
					<article-title>Evaluation of the osteoclastogenic process associated with RANK / RANK-L / OPG in odontogenic myxomas</article-title>
					<source>Med Oral Patol Oral Cir Bucal</source>
					<year>2018</year>
					<volume>23</volume>
					<issue>3</issue>
					<fpage>e315</fpage>
					<lpage>e319</lpage>
				</element-citation>
			</ref>
			<ref id="B5">
				<label>5</label>
				<mixed-citation>5. Kanitkar S, Kamat M, Tamagond S, Vareakr A, Datar U. Peripheral odontogenic myxoma in a 12-year-old girl: a rare entity. J Korean Assoc Oral Maxillofac Sur. 2017;43: 178.81. doi: 10.5125/jkaoms.2017.43.3.178</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Kanitkar</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Kamat</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Tamagond</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Vareakr</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Datar</surname>
							<given-names>U</given-names>
						</name>
					</person-group>
					<article-title>Peripheral odontogenic myxoma in a 12-year-old girl a rare entity</article-title>
					<source>J Korean Assoc Oral Maxillofac Sur</source>
					<year>2017</year>
					<volume>43</volume>
					<fpage>178</fpage>
					<lpage>178</lpage>
					<pub-id pub-id-type="doi">10.5125/jkaoms.2017.43.3.178</pub-id>
				</element-citation>
			</ref>
			<ref id="B6">
				<label>6</label>
				<mixed-citation>6. Chrcanovic BR, Gomez RS. Odontogenic myxoma: an updated analysis of 1,692 cases reported in the literature. Oral Dis. 2019; 25: 676-83. doi: 10.1111/odi.12875</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Chrcanovic</surname>
							<given-names>BR</given-names>
						</name>
						<name>
							<surname>Gomez</surname>
							<given-names>RS</given-names>
						</name>
					</person-group>
					<article-title>Odontogenic myxoma an updated analysis of 1,692 cases reported in the literature</article-title>
					<source>Oral Dis</source>
					<year>2019</year>
					<volume>25</volume>
					<fpage>676</fpage>
					<lpage>683</lpage>
					<pub-id pub-id-type="doi">10.1111/odi.12875</pub-id>
				</element-citation>
			</ref>
			<ref id="B7">
				<label>7</label>
				<mixed-citation>7. Bologna-Molina R, Mosqueda-Taylor A, Dominguez-Malagon H, Salazar-Rodriguez S, Tapia G, Gonzalez-Gonzalez R, Molina-Frechero N. Immunolocalization of VEGF-A and orosomucoid-1 in odontogenic myxoma. Rom J Morphol Embryol. 2015; 56 (2): 465-73.</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Bologna-Molina</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Mosqueda-Taylor</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Dominguez-Malagon</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Salazar-Rodriguez</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Tapia</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Gonzalez-Gonzalez</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Molina-Frechero</surname>
							<given-names>N</given-names>
						</name>
					</person-group>
					<article-title>Immunolocalization of VEGF-A and orosomucoid-1 in odontogenic myxoma</article-title>
					<source>Rom J Morphol Embryol</source>
					<year>2015</year>
					<volume>56</volume>
					<issue>2</issue>
					<fpage>465</fpage>
					<lpage>473</lpage>
				</element-citation>
			</ref>
			<ref id="B8">
				<label>8</label>
				<mixed-citation>8. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med. 1991; 32: 1-8.</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Weidner</surname>
							<given-names>N</given-names>
						</name>
						<name>
							<surname>Semple</surname>
							<given-names>JP</given-names>
						</name>
						<name>
							<surname>Welch</surname>
							<given-names>WR</given-names>
						</name>
						<name>
							<surname>Folkman</surname>
							<given-names>J</given-names>
						</name>
					</person-group>
					<article-title>Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma</article-title>
					<source>N Engl J Med</source>
					<year>1991</year>
					<volume>32</volume>
					<fpage>1</fpage>
					<lpage>8</lpage>
				</element-citation>
			</ref>
			<ref id="B9">
				<label>9</label>
				<mixed-citation>9. Martínez-Mata G, Mosqueda-Taylor A, Carlos-Bregni R, Paes de Almeida O, Contreras-Vidaurre E, Vargas PA, Cano-Valdéz AM, Domínguez-Malagón H. Odontogenic myxoma: clinico-pathological, immunohistochemical and ultrastructural findings of a multicentric series. Oral Oncol. 2007; 44: 601-7. doi:10.1016/j.oraloncology 2007.08.009.</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Martínez-Mata</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Mosqueda-Taylor</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Carlos-Bregni</surname>
							<given-names>R</given-names>
						</name>
					</person-group>
					<person-group person-group-type="author">
						<collab>Paes de Almeida O.Contreras-Vidaurre E.Vargas PA.Cano-Valdéz AM.Domínguez-Malagón H</collab>
					</person-group>
					<article-title>Odontogenic myxoma clinico-pathological, immunohistochemical and ultrastructural findings of a multicentric series</article-title>
					<source>Oral Oncol</source>
					<year>2007</year>
					<volume>44</volume>
					<fpage>601</fpage>
					<lpage>607</lpage>
					<pub-id pub-id-type="doi">10.1016/j.oraloncology</pub-id>
				</element-citation>
			</ref>
			<ref id="B10">
				<label>10</label>
				<mixed-citation>10. Lombardi T, Lock C, Samson J, Odell EW. S100, alpha-smooth muscle actin and cytokeratin19 immunohistochemistry in odontogenic and soft tissue myxomas. J Clin Pathol. 1995; 48: 759-62.</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Lombardi</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Lock</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Samson</surname>
							<given-names>J</given-names>
						</name>
						<name>
							<surname>Odell</surname>
							<given-names>EW</given-names>
						</name>
					</person-group>
					<article-title>S100, alpha-smooth muscle actin and cytokeratin19 immunohistochemistry in odontogenic and soft tissue myxomas</article-title>
					<source>J Clin Pathol</source>
					<year>1995</year>
					<volume>48</volume>
					<fpage>759</fpage>
					<lpage>762</lpage>
				</element-citation>
			</ref>
			<ref id="B11">
				<label>11</label>
				<mixed-citation>11. Etemad-Moghadam S, Alaeddinni M. A comparative study of syndecan-1 expression in different odontogenic tumors. J Oral Biol Craniofac Res. 2017; 7: 23-6. doi: 10.1016/j.jobcr.2016.11.001</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Etemad-Moghadam</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Alaeddinni</surname>
							<given-names>M</given-names>
						</name>
					</person-group>
					<article-title>A comparative study of syndecan-1 expression in different odontogenic tumors</article-title>
					<source>J Oral Biol Craniofac Res</source>
					<year>2017</year>
					<volume>7</volume>
					<fpage>23</fpage>
					<lpage>26</lpage>
					<pub-id pub-id-type="doi">10.1016/j.jobcr.2016.11.001</pub-id>
				</element-citation>
			</ref>
			<ref id="B12">
				<label>12</label>
				<mixed-citation>12. Bologna-Molina R, Salazar-Rodríguez S, Bedoya-Borella AM, Carreon-Burciaga RG, Tapia-Repetto G, Molina-Frechero N. A histopathological and immunohistochemical analysis of ameloblastic fibrodentinoma. Case Rep Pathol. 2013; 2013:604560. doi: 10.1155/2013/604560</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Bologna-Molina</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Salazar-Rodríguez</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Bedoya-Borella</surname>
							<given-names>AM</given-names>
						</name>
						<name>
							<surname>Carreon-Burciaga</surname>
							<given-names>RG</given-names>
						</name>
						<name>
							<surname>Tapia-Repetto</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Molina-Frechero</surname>
							<given-names>N</given-names>
						</name>
					</person-group>
					<article-title>A histopathological and immunohistochemical analysis of ameloblastic fibrodentinoma</article-title>
					<source>Case Rep Pathol</source>
					<year>2013</year>
					<volume>2013</volume>
					<fpage>604560</fpage>
					<lpage>604560</lpage>
					<pub-id pub-id-type="doi">10.1155/2013/604560</pub-id>
				</element-citation>
			</ref>
			<ref id="B13">
				<label>13</label>
				<mixed-citation>13. Bologna-Molina R, Mosqueda-Taylor A, López-Corella E, Paes de Almeida O, Carrasco-Daza D, Farfán-Morales JE, Molina-Frechero N, Damián-Matsumura P. Comparative expression of syndecan-1 and Ki-67 in peripheral and desmoplastic ameloblastomas and ameloblastic carcinoma. Pathol Int. 2009; 59: 229-33.</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Bologna-Molina</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Mosqueda-Taylor</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>López-Corella</surname>
							<given-names>E</given-names>
						</name>
					</person-group>
					<person-group person-group-type="author">
						<collab>Paes de Almeida O.Carrasco-Daza D.Farfán-Morales JE.Molina-Frechero N.Damián-Matsumura P</collab>
					</person-group>
					<article-title>Comparative expression of syndecan-1 and Ki-67 in peripheral and desmoplastic ameloblastomas and ameloblastic carcinoma</article-title>
					<source>Pathol Int</source>
					<year>2009</year>
					<volume>59</volume>
					<fpage>229</fpage>
					<lpage>233</lpage>
				</element-citation>
			</ref>
			<ref id="B14">
				<label>14</label>
				<mixed-citation>14. Manne RK, Kumar VS, Venkata Sarath P, Anumula L, Mundlapudi S, Tanikonda R. Odontogenic myxoma of the mandible. Case Rep Dent. 2012; 2012: 214704. doi: 10.1155/2012/214704</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Manne</surname>
							<given-names>RK</given-names>
						</name>
						<name>
							<surname>Kumar</surname>
							<given-names>VS</given-names>
						</name>
						<name>
							<surname>Venkata Sarath</surname>
							<given-names>P</given-names>
						</name>
						<name>
							<surname>Anumula</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Mundlapudi</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Tanikonda</surname>
							<given-names>R</given-names>
						</name>
					</person-group>
					<article-title>Odontogenic myxoma of the mandible</article-title>
					<source>Case Rep Dent</source>
					<year>2012</year>
					<volume>2012</volume>
					<fpage>214704</fpage>
					<lpage>214704</lpage>
					<pub-id pub-id-type="doi">10.1155/2012/214704</pub-id>
				</element-citation>
			</ref>
			<ref id="B15">
				<label>15</label>
				<mixed-citation>15. Alaeddini M, Etemad-Moghadam S, Baghaii F. Comparative expression of calretinin in selected odontogenic tumours: a possible relationship to histogenesis. Histopathology. 2008; 52 (3): 299-304.</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Alaeddini</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Etemad-Moghadam</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Baghaii</surname>
							<given-names>F</given-names>
						</name>
					</person-group>
					<article-title>Comparative expression of calretinin in selected odontogenic tumours a possible relationship to histogenesis</article-title>
					<source>Histopathology</source>
					<year>2008</year>
					<volume>52</volume>
					<issue>3</issue>
					<fpage>299</fpage>
					<lpage>304</lpage>
				</element-citation>
			</ref>
			<ref id="B16">
				<label>16</label>
				<mixed-citation>16. Terracciano LM, Mhawech P, Suess K, D'Armiento M, Lehmann FS, Jundt G, Moch H, Sauter G, Mihatsch MJ. Calretinin as a marker for cardic myxoma. Diagnostic and histogenetic considerations. Am J Clin Pathol. 2000; 114 (5): 754-9.</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Terracciano</surname>
							<given-names>LM</given-names>
						</name>
						<name>
							<surname>Mhawech</surname>
							<given-names>P</given-names>
						</name>
						<name>
							<surname>Suess</surname>
							<given-names>K</given-names>
						</name>
					</person-group>
					<person-group person-group-type="author">
						<collab>D'Armiento M.Lehmann FS.Jundt G.Moch H.Sauter G.Mihatsch MJ</collab>
					</person-group>
					<article-title>Calretinin as a marker for cardic myxoma Diagnostic and histogenetic considerations</article-title>
					<source>Am J Clin Pathol</source>
					<year>2000</year>
					<volume>114</volume>
					<issue>5</issue>
					<fpage>754</fpage>
					<lpage>759</lpage>
				</element-citation>
			</ref>
			<ref id="B17">
				<label>17</label>
				<mixed-citation>17. Mistry D, Altini M, Coleman HG, Ali H, Maiorano E. The spatial and temporal expression of calretinin in developing rat molars (Rattus norvegicus). Arch Oral Biol. 2001; 46 (10): 973-81.</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Mistry</surname>
							<given-names>D</given-names>
						</name>
						<name>
							<surname>Altini</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Coleman</surname>
							<given-names>HG</given-names>
						</name>
						<name>
							<surname>Ali</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Maiorano</surname>
							<given-names>E</given-names>
						</name>
					</person-group>
					<article-title>The spatial and temporal expression of calretinin in developing rat molars (Rattus norvegicus)</article-title>
					<source>Arch Oral Biol</source>
					<year>2001</year>
					<volume>46</volume>
					<issue>10</issue>
					<fpage>973</fpage>
					<lpage>981</lpage>
				</element-citation>
			</ref>
			<ref id="B18">
				<label>18</label>
				<mixed-citation>18. Altini M, Coleman H, Doglioni C, Favia G, Maiorano E. Calretinin expression in ameloblastomas. Histopatholohy. 2000; 37 (1): 27-32.</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Altini</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Coleman</surname>
							<given-names>H</given-names>
						</name>
						<name>
							<surname>Doglioni</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Favia</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Maiorano</surname>
							<given-names>E</given-names>
						</name>
					</person-group>
					<article-title>Calretinin expression in ameloblastomas</article-title>
					<source>Histopatholohy</source>
					<year>2000</year>
					<volume>37</volume>
					<issue>1</issue>
					<fpage>27</fpage>
					<lpage>32</lpage>
				</element-citation>
			</ref>
			<ref id="B19">
				<label>19</label>
				<mixed-citation>19. Seifi S, Shafaie S, Ghadiri S. Microvessel density in follicular cysts, keratocystic odontogenic tumours and ameloblastomas. Asian Pacific J Cancer Prev. 2001; 12 (2): 351-56.</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Seifi</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Shafaie</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Ghadiri</surname>
							<given-names>S</given-names>
						</name>
					</person-group>
					<article-title>Microvessel density in follicular cysts, keratocystic odontogenic tumours and ameloblastomas</article-title>
					<source>Asian Pacific J Cancer Prev</source>
					<year>2001</year>
					<volume>12</volume>
					<issue>2</issue>
					<fpage>351</fpage>
					<lpage>356</lpage>
				</element-citation>
			</ref>
			<ref id="B20">
				<label>20</label>
				<mixed-citation>20. Pereira T, Dodal S, Tamgadge A, Bhalerao S, Tamgadge S. Quantitative evaluation of microvessel density using CD34 in clinical variants of ameloblastoma: An immunohistochemical study. J Oral Maxillofac Pathol. 2016; 20 (1): 51-8. Doi: 10.4103/0973-029X.180929</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Pereira</surname>
							<given-names>T</given-names>
						</name>
						<name>
							<surname>Dodal</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Tamgadge</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Bhalerao</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Tamgadge</surname>
							<given-names>S</given-names>
						</name>
					</person-group>
					<article-title>Quantitative evaluation of microvessel density using CD34 in clinical variants of ameloblastoma: An immunohistochemical study</article-title>
					<source>J Oral Maxillofac Pathol</source>
					<year>2016</year>
					<volume>20</volume>
					<issue>1</issue>
					<fpage>51</fpage>
					<lpage>58</lpage>
				</element-citation>
			</ref>
			<ref id="B21">
				<label>21</label>
				<mixed-citation>21. Gupta B, Chandra S, Singh A, Sah K, Raj V, Gupta V. The role of vascular endothelial growth factor in proliferation of odontogenic cysts and tumors: An immunohistochemical study. Dent Res J. 2016; 13 (3): 256-63.</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Gupta</surname>
							<given-names>B</given-names>
						</name>
						<name>
							<surname>Chandra</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Singh</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Sah</surname>
							<given-names>K</given-names>
						</name>
						<name>
							<surname>Raj</surname>
							<given-names>V</given-names>
						</name>
						<name>
							<surname>Gupta</surname>
							<given-names>V</given-names>
						</name>
					</person-group>
					<article-title>The role of vascular endothelial growth factor in proliferation of odontogenic cysts and tumors An immunohistochemical study</article-title>
					<source>Dent Res J</source>
					<year>2016</year>
					<volume>13</volume>
					<issue>3</issue>
					<fpage>256</fpage>
					<lpage>263</lpage>
				</element-citation>
			</ref>
			<ref id="B22">
				<label>22</label>
				<mixed-citation>22. García-Muñoz A, Rodríguez MA, Bologna-Molina R, Cázares-Raga FE, Hernández-Hernández FC, Farfán-Morales JE, Trujillo JJ, Licéaga-Escalera C, Mendoza-Hernández G. The orosomucoid 1 protein (a1 acid glycoprotein) is overexpressed in odontogenic myxoma. Proteome Sci. 2012; 10 (1): 49.</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>García-Muñoz</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Rodríguez</surname>
							<given-names>MA</given-names>
						</name>
						<name>
							<surname>Bologna-Molina</surname>
							<given-names>R</given-names>
						</name>
						<name>
							<surname>Cázares-Raga</surname>
							<given-names>FE</given-names>
						</name>
						<name>
							<surname>Hernández-Hernández</surname>
							<given-names>FC</given-names>
						</name>
						<name>
							<surname>Farfán-Morales</surname>
							<given-names>JE</given-names>
						</name>
						<name>
							<surname>Trujillo</surname>
							<given-names>JJ</given-names>
						</name>
						<name>
							<surname>Licéaga-Escalera</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Mendoza-Hernández</surname>
							<given-names>G</given-names>
						</name>
					</person-group>
					<article-title>The orosomucoid 1 protein (a1 acid glycoprotein) is overexpressed in odontogenic myxoma</article-title>
					<source>Proteome Sci</source>
					<year>2012</year>
					<volume>10</volume>
					<issue>1</issue>
					<fpage>49</fpage>
					<lpage>49</lpage>
				</element-citation>
			</ref>
			<ref id="B23">
				<label>23</label>
				<mixed-citation>23. Irmak S, Oliveira-Ferrer L, Singer BB, Ergun S, Tilki D. Pro-angiogenic properties of orosomucoid (ORM). Exp Cell Res. 2009; 315 (18): 3201-09.</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Irmak</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Oliveira-Ferrer</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Singer</surname>
							<given-names>BB</given-names>
						</name>
						<name>
							<surname>Ergun</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Tilki</surname>
							<given-names>D</given-names>
						</name>
					</person-group>
					<article-title>Pro-angiogenic properties of orosomucoid (ORM)</article-title>
					<source>Exp Cell Res</source>
					<year>2009</year>
					<volume>315</volume>
					<issue>18</issue>
					<fpage>3201</fpage>
					<lpage>3209</lpage>
				</element-citation>
			</ref>
			<ref id="B24">
				<label>24</label>
				<mixed-citation>24. Ligresti G, Aplin AC, Dunn BE, Morishita A, Nicosia RF. The acute phase reactant orosomucoid-1 is a bimodal regulator of angiogenesis with time- and context dependent inhibitory and stimulatory properties. Plos One. 2012; 7 (8): e41387. doi: 10.1371/journal.pone.0041387</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Ligresti</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Aplin</surname>
							<given-names>AC</given-names>
						</name>
						<name>
							<surname>Dunn</surname>
							<given-names>BE</given-names>
						</name>
						<name>
							<surname>Morishita</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Nicosia</surname>
							<given-names>RF</given-names>
						</name>
					</person-group>
					<article-title>The acute phase reactant orosomucoid-1 is a bimodal regulator of angiogenesis with time- and context dependent inhibitory and stimulatory properties</article-title>
					<source>Plos One</source>
					<year>2012</year>
					<volume>7</volume>
					<issue>8</issue>
					<elocation-id>e41387</elocation-id>
					<pub-id pub-id-type="doi">10.1371/journal.pone.0041387</pub-id>
				</element-citation>
			</ref>
			<ref id="B25">
				<label>25</label>
				<mixed-citation>25. Kouhsoltani M, Halimi M, Dibazar S. A positive correlation between immunohistochemical expression of CD31 and mast cell tryptase in odontogenic tumor. Pol J Pathol. 2015; 66 (2): 170-5.</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Kouhsoltani</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Halimi</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Dibazar</surname>
							<given-names>S</given-names>
						</name>
					</person-group>
					<article-title>A positive correlation between immunohistochemical expression of CD31 and mast cell tryptase in odontogenic tumor</article-title>
					<source>Pol J Pathol</source>
					<year>2015</year>
					<volume>66</volume>
					<issue>2</issue>
					<fpage>170</fpage>
					<lpage>175</lpage>
				</element-citation>
			</ref>
			<ref id="B26">
				<label>26</label>
				<mixed-citation>26. Fajardo I, Pejler G. Human mast cell ß-tryptase is a gelatinase. J Immunol. 2003; 171 (3): 1493-9.</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Fajardo</surname>
							<given-names>I</given-names>
						</name>
						<name>
							<surname>Pejler</surname>
							<given-names>G</given-names>
						</name>
					</person-group>
					<article-title>Human mast cell ß-tryptase is a gelatinase</article-title>
					<source>J Immunol</source>
					<year>2003</year>
					<volume>171</volume>
					<issue>3</issue>
					<fpage>1493</fpage>
					<lpage>1499</lpage>
				</element-citation>
			</ref>
			<ref id="B27">
				<label>27</label>
				<mixed-citation>27. Huang S, Lu F, Chen Y, Huang B, Liu M. Mast cell degranulation in human periodontitis. J Periodontol. 2013; 84 (2): 248-55.</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Huang</surname>
							<given-names>S</given-names>
						</name>
						<name>
							<surname>Lu</surname>
							<given-names>F</given-names>
						</name>
						<name>
							<surname>Chen</surname>
							<given-names>Y</given-names>
						</name>
						<name>
							<surname>Huang</surname>
							<given-names>B</given-names>
						</name>
						<name>
							<surname>Liu</surname>
							<given-names>M</given-names>
						</name>
					</person-group>
					<article-title>Mast cell degranulation in human periodontitis</article-title>
					<source>J Periodontol</source>
					<year>2013</year>
					<volume>84</volume>
					<issue>2</issue>
					<fpage>248</fpage>
					<lpage>255</lpage>
				</element-citation>
			</ref>
			<ref id="B28">
				<label>28</label>
				<mixed-citation>28. De Assis Caldas Pereira F, Araújo Silva Gurgel CA, Ramos EA, Vidal MT, Pinheiro AL, Jurisic V, Sales CB, Cury PR, dos Santos JN. Distribution of mast cell in benign odontogenic tumors. Tumor Biol. 2012; 33 (2): 455-61.</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<collab>De Assis Caldas Pereira F.Araújo Silva Gurgel CA.Ramos EA.Vidal MT.Pinheiro AL.Jurisic V.Sales CB.Cury PR.dos Santos JN</collab>
					</person-group>
					<article-title>Distribution of mast cell in benign odontogenic tumors</article-title>
					<source>Tumor Biol</source>
					<year>2012</year>
					<volume>33</volume>
					<issue>2</issue>
					<fpage>455</fpage>
					<lpage>461</lpage>
				</element-citation>
			</ref>
			<ref id="B29">
				<label>29</label>
				<mixed-citation>29. Iezzi G, Piatelli A, Rubini C, Artese L, Fiorini M, Carinci F. MIB-1, Bcl-2 and p53 in odontogenic myxomas of the jaws. Acta Otorhinolaryngol Ital. 2007; 27 (5): 237-42.</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Iezzi</surname>
							<given-names>G</given-names>
						</name>
						<name>
							<surname>Piatelli</surname>
							<given-names>A</given-names>
						</name>
						<name>
							<surname>Rubini</surname>
							<given-names>C</given-names>
						</name>
						<name>
							<surname>Artese</surname>
							<given-names>L</given-names>
						</name>
						<name>
							<surname>Fiorini</surname>
							<given-names>M</given-names>
						</name>
						<name>
							<surname>Carinci</surname>
							<given-names>F</given-names>
						</name>
					</person-group>
					<article-title>MIB-1, Bcl-2 and p53 in odontogenic myxomas of the jaws</article-title>
					<source>Acta Otorhinolaryngol Ital</source>
					<year>2007</year>
					<volume>27</volume>
					<issue>5</issue>
					<fpage>237</fpage>
					<lpage>242</lpage>
				</element-citation>
			</ref>
			<ref id="B30">
				<label>30</label>
				<mixed-citation>30. Bast B, Pogrel MA, Regezi JA. The expression of apoptotic proteins and matrix metalloproteinases in odontogenic myxomas. J Oral Maxillofac Surg. 2003; 61 (12): 1463-6.</mixed-citation>
				<element-citation publication-type="journal">
					<person-group person-group-type="author">
						<name>
							<surname>Bast</surname>
							<given-names>B</given-names>
						</name>
						<name>
							<surname>Pogrel</surname>
							<given-names>MA</given-names>
						</name>
						<name>
							<surname>Regezi</surname>
							<given-names>JA</given-names>
						</name>
					</person-group>
					<article-title>The expression of apoptotic proteins and matrix metalloproteinases in odontogenic myxomas</article-title>
					<source>J Oral Maxillofac Surg</source>
					<year>2003</year>
					<volume>61</volume>
					<issue>12</issue>
					<fpage>1463</fpage>
					<lpage>1466</lpage>
				</element-citation>
			</ref>
		</ref-list>
		<fn-group>
		<fn fn-type="other" id="fn1">
			<label>Contribución de Autoría:</label>
			<p> 1. Concepción y diseño del estudio 2. Adquisición de datos 3. Análisis de datos 4. Discusión de resultados 5.Redacción del manuscrito 6. Aprobación de la versión final del manuscrito ZGH, CSR y RBM han contribuido en 1, 2, 3, 4, 5 y 6. GVB y VPP han contribuido en 3, 4, 5 y 6 ES ha contribuido en 4, 5 y 6 OTM ha contribuido en 1, 2, y 3</p>
		</fn>
		<fn fn-type="other" id="fn2">
			<label>Nota de aceptación:</label>
			<p> Este artículo fue aprobado por la editora de la revista Mag. Dra. Vanessa Pereira-Prado</p>
		</fn>
	</fn-group>
	</back>
	<!--sub-article article-type="translation" id="s1" xml:lang="en">
		<front-stub>
			<article-categories>
				<subj-group subj-group-type="heading">
					<subject>Research</subject>
				</subj-group>
			</article-categories>
			<title-group>
				<article-title>Immunohistochemical profile of odontogenic myxoma, with emphasis on microvascular density and tumor aggressiveness markers</article-title>
			</title-group>
			<abstract>
				<title>Abstract:</title>
				<p>In order to elucidate better the biological behavior of the odontogenic myxoma (OM), immunohistochemistry was performed in 31 samples, using markers related to mechanisms of tumor progression (adhesion, angiogenesis, apoptosis, inflammation and cell proliferation). Odontogenic epithelium was detected in four samples with CK19 and CD138, the latter had a low-expression in extracellular matrix (ECM) and a high-expression in tumor cells. The mean microvascular density (MVD) assessed with CD34 and VEGF-A, was 7.51 and 5.35 blood vessels respectively. A high-expression of Orosomucoid-1 and Mast Cell Tryptase was observed in tumor cells and ECM, while Calretinin was completely negative. The previously mentioned immunohistochemical profile, as well as the low expression of Ki-67, Bcl-2 and p53 and the relatively low MVD, suggests that the proliferative, anti-apoptotic and angiogenic activities do not represent the main growing mechanisms of OM, which could be associated to other events, such as immunomodulation and ECM degradation.</p>
			</abstract>
			<kwd-group xml:lang="en">
				<title>Keywords:</title>
				<kwd>odontogenic myxoma</kwd>
				<kwd>immunohistochemistry</kwd>
				<kwd>tumoral markers</kwd>
				<kwd>angiogenesis.</kwd>
			</kwd-group>
		</front-stub>
		<body>
			<sec sec-type="intro">
				<title>Introduction</title>
				<p>Odontogenic tumors (OT) include a group of lesions that primarily affect the gnathic bones, ranging from hamartomas to benign neoplasms and malignant tumors <xref ref-type="bibr" rid="B1"><sup>1</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B2"><sup>2</sup></xref>. Odontogenic myxomas (OM) are benign mesenchymal OT (with or without odontogenic epithelium); however, they exhibit an aggressive behavior: significant growth potential as well as a high recurrence rate (25%) <xref ref-type="bibr" rid="B3"><sup>3</sup></xref>.</p>
				<p>Globally, OM represent between 2.2 and 17% of OT and affect mainly the posterior mandible, and occasionally the maxilla <xref ref-type="bibr" rid="B4"><sup>4</sup></xref>. Rare cases of peripheral OM have been reported, and they are less aggressive than central OM <xref ref-type="bibr" rid="B5"><sup>5</sup></xref>. OM occurs more frequently between the second and fourth decades of life (mean age of 28.6 years), and its clinical presentation is a slow growing volume increase, which is usually asymptomatic <xref ref-type="bibr" rid="B6"><sup>6</sup></xref>, so it may be large sized when diagnosed. Radiographically, its appearance may be unilocular (small lesions), or more commonly multilocular (classically described as “tennis racket” pattern) <xref ref-type="bibr" rid="B3"><sup>3</sup></xref>.</p>
				<p>Microscopically, OM typically have fusiform to stellate cells dispersed in an abundant myxoid matrix composed mainly of glycosaminoglycans, which may or not have islands of odontogenic epithelium; the presence of collagen fibers is variable <xref ref-type="bibr" rid="B3"><sup>3</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B4"><sup>4</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B6"><sup>6</sup></xref>.</p>
				<p>To date, there are few papers describing the molecular components of OM, so this study aims to determine the immunohistochemical profile of various tumor markers and to analyze microvascular density (MVD) in order to discuss its possible implications for the biological behavior of OM.</p>
			</sec>
			<sec sec-type="methods">
				<title>Methodology</title>
				<sec>
					<title>Sample selection</title>
					<p>Thirty-one cases of mandibular OM obtained from the Molecular Pathology Area of the School of Dentistry, Universidad de la República (Uruguay) were included. The samples were obtained by incisional biopsy, fixed in 10% formaldehyde and then included in paraffin blocks. This study was approved by the Ethics Committee of the School of Dentistry of Universidad de la República, under protocol number 091900-000113-14. Informed consent was obtained from all the study participants when the biopsy was performed.</p>
				</sec>
				<sec>
					<title>Immunohistochemistry</title>
					<p>For immunohistochemistry assays, 3µm sections of paraffin embedded OM tissues were made and placed on slides; they were then deparaffinized in xylol and subsequently hydrated with decreasing concentrations of alcohol. Antigen retrieval was performed with a citrate solution (pH 6.2) in a pressure cooker in microwave oven on full power for one minute. Endogenous peroxidases were blocked with hydrogen peroxide at 0.9% for 5 minutes. Primary antibodies were incubated for one hour (<xref ref-type="table" rid="t4">Table 1</xref>).</p>
					<p>
						<table-wrap id="t4">
							<label>Table 1:</label>
							<caption>
								<title>Data of antibodies used in this study</title>
							</caption>
							<graphic xlink:href="1688-9339-ode-22-35-52-gt4.jpg"/>
						</table-wrap>
					</p>
					<p>Later the sections were incubated with the secondary biotinylated anti-mouse/anti-rabbit antibody and with the streptavidin/peroxidase complex (LSA-B + Dako Corporation, Carpinteria CA, USA) for 30 minutes each. The reaction was visualized with 3.3’-diaminobenzidine-H2O2 substrate (Dako Corporation, Carpinteria, CA, USA). Finally, the sections were contrasted with Mayer’s hematoxylin.</p>
					<p>The following positive controls were used: oral mucosa for CK19 and CD138; breast cancer for calretinin; oral carcinoma for orosomucoid-1 and p53; intestine for mast cell tryptase, CD34 and VEGF-A; and tonsil for Bcl-2 and Ki-67.</p>
				</sec>
				<sec>
					<title>Microscopic examination</title>
					<p>Reactions were considered positive when brown labeling was observed in cells (tumor cells, endothelial cells or islands of odontogenic epithelium), or in extracellular matrix (ECM). Labeling patterns (nuclear, cytoplasmic, membranous, or ECM) varied for each type of antibody.</p>
					<p><italic>Proteins assessed in islands of odontogenic epithelium: CK19 and CD138</italic></p>
					<p>Using an optical microscope, each section was fully visualized under a 10x objective to identify areas with positive results and then at 40x to confirm it was odontogenic epithelium. The result was expressed as positive or negative.</p>
					<p><italic>Proteins assessed in tumor cells and ECM: CD138, calretinin, orosomucoid-1, mast cell tryptase, Bcl-2, Ki-67, p53 and VEGF-A</italic></p>
					<p>The complete sections were visualized under the 40x objective to determine the immunoexpression percentage throughout the tumor tissue on the slide. Percentages were classified into four groups: 0%, negative expression; 1% to 10%, low expression; 11% to 50%, moderate expression and greater than 50%, high expression <xref ref-type="bibr" rid="B7"><sup>7</sup></xref>.</p>
					<p><italic>Proteins assessed in blood vessels: VEGF-A and CD34</italic></p>
					<p>The method described by Weidner et al. was used to determine MVD. Tissues were initially visualized using a 10x objective to identify three areas with the highest concentration of positive vessels (<italic>hot spots</italic>), where vessel counting was performed manually using a 40x objective. Finally, the average number of vessels in the five fields of each sample was calculated <xref ref-type="bibr" rid="B8"><sup>8</sup></xref>.</p>
				</sec>
			</sec>
			<sec sec-type="results">
				<title>Results</title>
				<p>Odontogenic epithelium positive for CK19 and CD138 was detected in four cases. Additionally, CD138 showed high immunopositivity in tumor cells from most samples (74.2%) and low expression in ECM in 38.7% of cases (<xref ref-type="fig" rid="f3">Figures 1</xref>A, B).</p>
				<p>Calretinin was negative in all OM samples. In contrast, high immunopositivity of orosomucoid-1 was observed in tumor cells as well as ECM in 100% of cases, while mast cell tryptase was detected in the form of mast cell granules, focusing on ECM and with high expression in tumor cells: 96.7% of cases (n=30) (<xref ref-type="fig" rid="f2">Figures 2</xref> A, D) (<xref ref-type="fig" rid="f4">Figures 2</xref> C, E, F).</p>
				<p>Low labelling for Bcl-2 (cytoplasmic), Ki-67 (nuclear) and p53 (nuclear) was observed in tumor cells (n=18, 58.1%; n=28, 90.3% and n=12, 38.7% respectively).</p>
				<p>CD34 and VEGF-A were positive in endothelial cells (blood vessels). Additionally, VEGF-A showed a predominantly high expression in OM tumor cells (n=24, 77.5%) (<xref ref-type="table" rid="t5">Table 2</xref>). MVD was 7.51 and 5.35 for CD34 and VEGF-A respectively (<xref ref-type="fig" rid="f3">Figures 1</xref>C and <xref ref-type="fig" rid="f4">2D</xref>).</p>
				<p>Most proteins that were detected in tumor cells and ECM showed a high immunoexpression, except for Bcl-2. <xref ref-type="table" rid="t6">Table 3</xref> shows the pattern, level and immunoexpression distribution of each protein in OM cases.</p>
				<p>
					<fig id="f3">
						<label>Fig. 1:</label>
						<caption>
							<title>Immunohistochemical markers in OM. Small islands of odontogenic epithelium were positive for CK19 (A) and CD138 (B), which was also expressed in tumor cells and ECM. Only endothelial cells in blood vessels were positive for CD34 (C). (Original magnification, A-C: 400x).</title>
						</caption>
						<graphic xlink:href="1688-9339-ode-22-35-52-gf3.jpg"/>
					</fig>
				</p>
				<p>
					<fig id="f4">
						<label>Fig. 2:</label>
						<caption>
							<title>Immunohistochemical profile of OM. High immunopositivity for orosomucoid-1 in tumor cells, endothelial cells and ECM (A). VEGF-A expression in tumor cells and endothelial cells (B). Bcl-2 expression in some tumor cells (C). Mast cell tryptase showed intense positivity with granular appearance in tumor cells, mast cells and ECM (D). Few nuclei positive for Ki-67 (E) and p53 (F). (Original magnification, A, B, C, E, F: 400x; D: 600x).</title>
						</caption>
						<graphic xlink:href="1688-9339-ode-22-35-52-gf4.jpg"/>
					</fig>
				</p>
				<p>
					<table-wrap id="t5">
						<label>Table 2:</label>
						<caption>
							<title>Distribution of marker expression in OM components</title>
						</caption>
						<graphic xlink:href="1688-9339-ode-22-35-52-gt5.jpg"/>
						<table-wrap-foot>
							<fn id="TFN3">
								<p>Abbreviations. TC: tumor cells, ECM: extracellular matrix, OE: odontogenic epithelium, BV: blood vessels.</p>
							</fn>
						</table-wrap-foot>
					</table-wrap>
				</p>
				<p>
					<table-wrap id="t6">
						<label>Table 3:</label>
						<caption>
							<title>Number and percentage of cases according to immunoexpression level</title>
						</caption>
						<graphic xlink:href="1688-9339-ode-22-35-52-gt6.jpg"/>
						<table-wrap-foot>
							<fn id="TFN4">
								<p>Abbreviations. TC: tumor cells, M: mast cells. ECM: extracellular matrix. * VEGF-A expression in endothelial cells was quantified as microvascular density (see results section). </p>
							</fn>
						</table-wrap-foot>
					</table-wrap>
				</p>
			</sec>
			<sec sec-type="discussion">
				<title>Discussion</title>
				<p>It has been suggested that OM has an odontogenic origin based on the occasional presence of small islands of odontogenic epithelium, its appearance in the mandible and maxilla, and its histomorphological similarity to the mesenchymal tissue of the tooth germ <xref ref-type="bibr" rid="B9"><sup>9</sup></xref>.</p>
				<p>In this study, 13.3% of the sample had CD138 and CK19 positive odontogenic epithelial islands. This is consistent with two previous studies where epithelial islands were detected using CK19 in 4.8% and 14% of cases <xref ref-type="bibr" rid="B9"><sup>9</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B10"><sup>10</sup></xref><sup>).</sup> Additionally, our results ratify the usefulness of CD138 as an alternative marker of odontogenic epithelium in OM.</p>
				<p>A high expression of CD138 was observed in tumor cells in most cases (73.30%), while in ECM, immunoexpression was mainly low (46.70% of cases). Contrary to our results, in the study conducted by Etemad-Moghadam et al. (2017), CD138 was negative in all the samples <xref ref-type="bibr" rid="B11"><sup>11</sup></xref>. The physiological role of CD138, jointly with the ECM, is to participate in the induction and regulation of proliferation by interacting with families of heparin-binding growth factors <xref ref-type="bibr" rid="B12"><sup>12</sup></xref>. Additionally, it interacts with other ECM components <xref ref-type="bibr" rid="B13"><sup>13</sup></xref>, some of which (type I collagen, fibronectin and tenascin) are part of the ECM of the OM <xref ref-type="bibr" rid="B14"><sup>14</sup></xref>. This suggests that, in addition to the structural maintenance function of an epithelial adhesion protein, upon release into the ECM, CD138 could participate in various signaling pathways by interacting with growth factors and other molecules present in the ECM.</p>
				<p>Although calretinin expression has been described in ameloblastomas, and has been associated with enamel production in tooth germ, in this study it was negative in OM, as in previous studies <xref ref-type="bibr" rid="B15"><sup>15</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B16"><sup>16</sup></xref>. This absence of calretinin can be explained by the mesenchymal origin of OM, unlike ameloblastomas and the enamel organ <xref ref-type="bibr" rid="B17"><sup>17</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B18"><sup>18</sup></xref>.</p>
				<p>A previous study determined MVD in OM by CD34 expression, with similar results to ours <xref ref-type="bibr" rid="B7"><sup>7</sup></xref>. Ameloblastoma has higher MVD compared to other odontogenic tumors and cysts, suggesting an association with a more aggressive behavior <xref ref-type="bibr" rid="B19"><sup>19</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B20"><sup>20</sup></xref>. In our study, MVD in OM was five times lower than in the ameloblastomas of the study conducted by Seifi et al. (2001), suggesting that angiogenesis could partially contribute to tumor growth in OM <xref ref-type="bibr" rid="B19"><sup>19</sup></xref>.</p>
				<p>In OM, VEGF-A (one of the majors signaling proteins for angiogenesis) was expressed in endothelial cells and tumor cells. Recent researches suggest that VEGF-A immunoexpression in the epithelium of odontogenic cysts and epithelial OT, such as ameloblastoma, affects epithelial proliferation through an autocrine signaling, whereas angiogenic activity is mediated by a paracrine mechanism <xref ref-type="bibr" rid="B7"><sup>7</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B21"><sup>21</sup></xref>. However, in the only study describing VEGF-A expression in MO, it has been associated primarily with the angiogenic mechanisms of this tumor <xref ref-type="bibr" rid="B7"><sup>7</sup></xref>.</p>
				<p>In the OM samples tested, high orosomucoid-1 immunoexpression was observed in tumor cells and ECM. This confirms the findings of the two studies that reported orosomucoid-1 overexpression in OM by immunohistochemistry and proteomics <xref ref-type="bibr" rid="B7"><sup>7</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B22"><sup>22</sup></xref>.</p>
				<p>Macroscopically, OM appears as a highly viscous mucous mass, which, according to our results, could be partly due to the presence of orosomucoid-1 (which is a mucoprotein) in the ECM. It is widely accepted that the structural viscosity of the OM enables it to infiltrate bone and invade <xref ref-type="bibr" rid="B7"><sup>7</sup></xref>. In turn, García Muñoz et al. (2012) proposed that overexpression of orosomucoid-1 in OM could play a major role in tumor cell growth and invasion potential by inhibiting antitumor immune response <xref ref-type="bibr" rid="B22"><sup>22</sup></xref>.</p>
				<p>Orosomucoid-1 has been shown to participate in VEGF-A regulation and induction <xref ref-type="bibr" rid="B23"><sup>23</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B24"><sup>24</sup></xref>. Thus, overexpression of these proteins in OM in both, tumor and endothelial cells, could indicate an interaction between orosomucoid-1 and VEGF-A in this tumor, suggesting a collaborative proangiogenic role <xref ref-type="bibr" rid="B7"><sup>7</sup></xref>.</p>
				<p>In this study, most cases expressed high immunopositivity for mast cell tryptase (96.70%) in tumor cells, mast cells, and the ECM. A previous study including seven cases of OM reported no expression of mast cell tryptase; however, the sample size may not be representative <xref ref-type="bibr" rid="B25"><sup>25</sup></xref>. Another study conducted in a larger sample (62 cases) found mast cell tryptase in 72.6% of OM and it was mainly located in mast cells, which have large amounts of active tryptase stored, than, when released, can degrade fibronectin (one of the components of the OM’s ECM). This suggests that, to some extent, ECM degradation could be mediated by the release of mast cell tryptase <xref ref-type="bibr" rid="B9"><sup>9</sup></xref><sup>-</sup><xref ref-type="bibr" rid="B26"><sup>26</sup></xref>. Additionally, there is an association between the presence of mast cells and mast cell tryptase with bone resorption in odontogenic cysts <xref ref-type="bibr" rid="B27"><sup>27</sup></xref>, and although the incidence of mast cells in OM varies according to different studies, it has been described that these cells are frequently distributed adjacent to residual bone trabeculae <xref ref-type="bibr" rid="B28"><sup>28</sup></xref>. These findings suggest that ECM degradation and bone remodeling processes via tryptase contribute significantly to the invasion potential of OM <sup>(27, -28)</sup>.</p>
				<p>The imbalance between apoptosis mechanisms and cell proliferation accounts for significant tumorigenic molecular alterations in various neoplasms.</p>
				<p>In this study we evaluated p53, Bcl-2 and Ki-67, which are proteins related to apoptotic, anti-apoptotic and cell proliferation processes respectively. The apoptosis induced by p53 has been shown to be blocked by Bcl-2 <xref ref-type="bibr" rid="B29"><sup>29</sup></xref>. Both markers, p53 and Bcl-2, showed a low immunoexpression in most OM, which is consistent with previous reports <xref ref-type="bibr" rid="B9"><sup>9</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B30"><sup>30</sup></xref>. Likewise, Ki-67 showed a low proliferation rate in our cases, which is consistent with the work of various authors <xref ref-type="bibr" rid="B9"><sup>9</sup></xref><sup>,</sup><xref ref-type="bibr" rid="B30"><sup>30</sup></xref>. These results could indicate that, due to the low level of anti-apoptotic and proliferative activity in this tumor, these would not be the main mechanisms associated with the growth potential and aggressiveness of OM.</p>
			</sec>
			<sec sec-type="conclusions">
				<title>Conclusions</title>
				<p>CK19 and CD138 labelling is useful for detecting odontogenic epithelium in OM. The high expression of orosomucoid-1 in the ECM may indicate it is a structural component that contributes to its viscosity and, therefore, facilitates invasion. Orosomucoid-1 also showed a VEGF-A-like pattern in tumor and endothelial cells, suggesting proangiogenic collaborative activity, possibly involved in tumor development. Anti-apoptotic and proliferative activity do not seem to be crucial mechanisms in the aggressive behavior of OM. However, ECM degradation and bone resorption mediated by mast cell tryptase could be significant in the high invasive potential of OM.</p>
			</sec>
		</body>
		<back>
			<fn fn-type="other" id="fn3">
				<label>Authorship contribution:</label>
				<p> 1. Conception and design of study 2. Acquisition of data 3. Data analysis 4. Discussion of results 5. Drafting of the manuscript 6. Approval of the final version of the manuscript ZGH, CSR and RBM have contributed in 1,2,3,4,5,6. GVB and VPP have contributed in 3,4,5,6. ES has contributed in 4,5,6. OTM has contributed in 1,2,3.</p>
			</fn>
			<fn fn-type="other" id="fn4">
				<label>Editor’s opinion:</label>
				<p> This article has been accepted by the Odontoestomatología’s editor Dra. Vanessa Pereira-Prado</p>
			</fn>
		</back>
	</sub-article-->
</article>